CBDX (Curative Biosciences) ROCE %: 0.00% (As of Mar. 2018)


What is Curative Biosciences ROCE %?

Curative Biosciences CBDX ROCE % is 0.00% as of Mar. 2018.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Curative Biosciences's annualized ROCE % for the quarter that ended in Mar. 2018 was 0.00%.

Curative Biosciences  (OTCPK:CBDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Curative Biosciences ROCE % Related Terms

Curative Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences ROCE % Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Curative Biosciences ROCE % Calculation

Curative Biosciences's annualized ROCE % for the fiscal year that ended in Jun. 2017 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=-0.053/( ( (0.005 - 0.62) + (0.002 - 0.633) )/ 2 )
=-0.053/( (-0.615+-0.631)/ 2 )
=-0.053/-0.623
=8.51 %

Curative Biosciences's ROCE % of for the quarter that ended in Mar. 2018 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2018 )  (Q: Dec. 2017 )(Q: Mar. 2018 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2018 )  (Q: Dec. 2017 )(Q: Mar. 2018 )
=-0.128/( ( (0.001 - 0.675) + (0.014 - 0.72) )/ 2 )
=-0.128/( ( -0.674 + -0.706 )/ 2 )
=-0.128/-0.69
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Curative Biosciences (CBDX) has a ROCE % of 0.00% as of Mar. 2018.
Is Curative Biosciences' ROCE % too high?
Curative Biosciences' current ROCE % is 0.00%.
How does Curative Biosciences' ROCE % compare to ACUR and CVLB?
Curative Biosciences' ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curative Biosciences's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current ROCE % is 0.00% as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.